TBPH Stock Earnings Theravance Biopharma Beats EPS, Misses Revenue for Q2 2024

TBPH Stock  USD 9.42  0.18  1.95%   
Under 53% of Theravance Biopharma's investor base is interested to short. The analysis of overall sentiment of trading Theravance Biopharma stock suggests that many investors are impartial at this time. Theravance Biopharma's investing sentiment shows overall attitude of investors towards Theravance Biopharma.
  
TBPH stock results show that Theravance Biopharma beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

Read at investorplace.com
sbwire news
  

Theravance Biopharma Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Theravance Biopharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Theravance Biopharma Fundamental Analysis

We analyze Theravance Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Theravance Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Theravance Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Total Asset

Total Asset Comparative Analysis

Theravance Biopharma is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Theravance Biopharma Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Theravance Biopharma stock to make a market-neutral strategy. Peer analysis of Theravance Biopharma could also be used in its relative valuation, which is a method of valuing Theravance Biopharma by comparing valuation metrics with similar companies.

Peers

Theravance Biopharma Related Equities

TILInstil Bio   16.79   
0%
100.0%
ASMBAssembly Biosciences   10.72   
0%
63.0%
CTMXCytomX Therapeutics   6.25   
0%
37.0%
CNTBConnect Biopharma   6.19   
0%
36.0%
SNSESensei Biotherapeutics   5.66   
0%
33.0%
NUVBNuvation Bio   3.21   
0%
19.0%
OVIDOvid Therapeutics   1.83   
0%
10.0%
ACHLAchilles Therapeutics   0.94   
0%
5.0%
NXTCNextCure   2.50   
14.0%
0%

Complementary Tools for Theravance Stock analysis

When running Theravance Biopharma's price analysis, check to measure Theravance Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theravance Biopharma is operating at the current time. Most of Theravance Biopharma's value examination focuses on studying past and present price action to predict the probability of Theravance Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theravance Biopharma's price. Additionally, you may evaluate how the addition of Theravance Biopharma to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Money Managers
Screen money managers from public funds and ETFs managed around the world
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings